MARCELO FELIPE KUPERMAN BENVENISTE
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thymus Neoplasms | 9 | 2021 | 400 | 2.480 |
Why?
|
| Neoplasms, Glandular and Epithelial | 5 | 2021 | 519 | 1.800 |
Why?
|
| Diagnostic Imaging | 8 | 2021 | 1162 | 1.610 |
Why?
|
| Thymoma | 4 | 2015 | 246 | 1.130 |
Why?
|
| Lung Neoplasms | 16 | 2021 | 11538 | 1.040 |
Why?
|
| Radiotherapy | 3 | 2019 | 1824 | 0.990 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2021 | 7551 | 0.980 |
Why?
|
| Lung | 9 | 2021 | 3151 | 0.970 |
Why?
|
| Mediastinal Neoplasms | 4 | 2017 | 423 | 0.940 |
Why?
|
| Thorax | 2 | 2021 | 213 | 0.870 |
Why?
|
| Radiation Injuries | 3 | 2019 | 1411 | 0.770 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2022 | 1226 | 0.700 |
Why?
|
| Pleural Neoplasms | 3 | 2021 | 470 | 0.690 |
Why?
|
| Radiography | 3 | 2019 | 1904 | 0.660 |
Why?
|
| Positron-Emission Tomography | 9 | 2022 | 2173 | 0.650 |
Why?
|
| Lymphatic Metastasis | 6 | 2021 | 4844 | 0.640 |
Why?
|
| Positron Emission Tomography Computed Tomography | 9 | 2022 | 833 | 0.630 |
Why?
|
| Mediastinum | 2 | 2017 | 268 | 0.600 |
Why?
|
| Radiopharmaceuticals | 7 | 2022 | 1301 | 0.590 |
Why?
|
| Thoracic Neoplasms | 3 | 2016 | 337 | 0.580 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 388 | 0.560 |
Why?
|
| Multimodal Imaging | 3 | 2014 | 550 | 0.550 |
Why?
|
| Heart | 2 | 2019 | 1223 | 0.520 |
Why?
|
| Multidetector Computed Tomography | 4 | 2017 | 150 | 0.470 |
Why?
|
| Lipoma | 1 | 2013 | 89 | 0.450 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2014 | 123 | 0.450 |
Why?
|
| Breast | 2 | 2019 | 1344 | 0.440 |
Why?
|
| Mesothelioma | 1 | 2017 | 544 | 0.420 |
Why?
|
| Lymph Nodes | 6 | 2021 | 2967 | 0.400 |
Why?
|
| Image Enhancement | 2 | 2014 | 561 | 0.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2021 | 5319 | 0.370 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 1248 | 0.360 |
Why?
|
| Esophageal Neoplasms | 5 | 2022 | 3168 | 0.350 |
Why?
|
| Neoplasm Staging | 14 | 2021 | 13658 | 0.330 |
Why?
|
| Lung Diseases | 2 | 2014 | 717 | 0.320 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 2370 | 0.310 |
Why?
|
| Humans | 46 | 2022 | 261506 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 7702 | 0.280 |
Why?
|
| Adenocarcinoma | 4 | 2017 | 7789 | 0.240 |
Why?
|
| Pulmonary Embolism | 2 | 2020 | 329 | 0.240 |
Why?
|
| Pulmonary Artery | 2 | 2020 | 499 | 0.240 |
Why?
|
| Radiography, Thoracic | 2 | 2019 | 462 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4757 | 0.210 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 509 | 0.200 |
Why?
|
| Radiation Dosage | 2 | 2019 | 1014 | 0.200 |
Why?
|
| Artifacts | 2 | 2015 | 532 | 0.200 |
Why?
|
| Carcinoma | 2 | 2022 | 2578 | 0.180 |
Why?
|
| Mammography | 2 | 2017 | 1010 | 0.180 |
Why?
|
| Thymus Gland | 1 | 2021 | 294 | 0.180 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 4744 | 0.170 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 276 | 0.160 |
Why?
|
| Bevacizumab | 2 | 2018 | 938 | 0.150 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 62 | 0.150 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 79 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 14889 | 0.140 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.130 |
Why?
|
| Neoplasms | 2 | 2021 | 15193 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2019 | 619 | 0.130 |
Why?
|
| Thoracic Wall | 1 | 2016 | 183 | 0.120 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2014 | 160 | 0.120 |
Why?
|
| Carcinoid Tumor | 2 | 2013 | 280 | 0.120 |
Why?
|
| Middle Aged | 15 | 2020 | 86204 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 781 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 941 | 0.120 |
Why?
|
| Male | 15 | 2020 | 123000 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 304 | 0.110 |
Why?
|
| Thymectomy | 1 | 2013 | 79 | 0.110 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2013 | 37 | 0.110 |
Why?
|
| Quinazolines | 1 | 2017 | 923 | 0.110 |
Why?
|
| Airway Obstruction | 1 | 2014 | 261 | 0.100 |
Why?
|
| Risk Factors | 3 | 2019 | 17523 | 0.100 |
Why?
|
| Myocardium | 1 | 2018 | 1313 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 1249 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2018 | 1529 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 592 | 0.100 |
Why?
|
| Pyridines | 1 | 2017 | 1244 | 0.090 |
Why?
|
| Dyspnea | 1 | 2013 | 416 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2022 | 37905 | 0.090 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2013 | 261 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1363 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2018 | 1330 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2017 | 1471 | 0.080 |
Why?
|
| Female | 14 | 2020 | 141928 | 0.080 |
Why?
|
| Stents | 1 | 2014 | 1096 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2017 | 32848 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2104 | 0.070 |
Why?
|
| Aged | 10 | 2020 | 70117 | 0.070 |
Why?
|
| Biopsy | 1 | 2014 | 3443 | 0.070 |
Why?
|
| Prognosis | 3 | 2016 | 21713 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1577 | 0.070 |
Why?
|
| Esophagus | 2 | 2021 | 553 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2018 | 6869 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 6009 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 29902 | 0.060 |
Why?
|
| Adult | 7 | 2020 | 77950 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 7548 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 4971 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 10035 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 15694 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5437 | 0.050 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 60 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 388 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 756 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2018 | 9180 | 0.030 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 242 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 155 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 14289 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 2014 | 45 | 0.030 |
Why?
|
| Tracheal Diseases | 1 | 2014 | 32 | 0.030 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 380 | 0.030 |
Why?
|
| Young Adult | 1 | 2013 | 21445 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 295 | 0.030 |
Why?
|
| Papilloma | 1 | 2013 | 74 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 355 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2316 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 2961 | 0.030 |
Why?
|
| Hamartoma | 1 | 2013 | 115 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 671 | 0.030 |
Why?
|
| Breast Diseases | 1 | 2014 | 201 | 0.030 |
Why?
|
| Hemangioma | 1 | 2013 | 154 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 361 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 1204 | 0.020 |
Why?
|
| Logistic Models | 1 | 2018 | 3441 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 408 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 551 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 1271 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1959 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3981 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2295 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4892 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 3842 | 0.020 |
Why?
|
| Mutation | 2 | 2018 | 15179 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5112 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2330 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 10001 | 0.020 |
Why?
|
| Palliative Care | 1 | 2017 | 2037 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 9244 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 4988 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 12221 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6207 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 10331 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 31252 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 15862 | 0.010 |
Why?
|
| Child | 1 | 2013 | 29154 | 0.010 |
Why?
|